COMMUNIQUÉS West-GlobeNewswire

Immutep Receives ~A$0.86 Million R&D Tax Incentive
30/09/2026
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces [...]
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
30/09/2026
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration – WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica [...]
DiFusion Activates Operating Board to Scale Therapeutic Biomaterials Platform
30/09/2026
Five-member board brings hands-on leadership in biomaterials commercialization, medical technology, spine innovation, OEM conversion and capital formation as DiFusion advances from cleared ZFUZE® devices into peptide- [...]
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
30/09/2026
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and [...]
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
30/09/2026
LONDON and PHILADELPHIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today publishes its unaudited [...]
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
30/09/2026
- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with [...]
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
30/09/2026
FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP [...]
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
30/09/2026
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic setting REVTORPYK [...]
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
30/09/2026
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million [...]
Vision Alive Max by Holistic Health Labs Features MaquiBright®, the Clinically Studied Maqui Berry Extract at the Research-Matched Dose
30/09/2026
New York, USA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Holistic Health Labs has announced that Vision Alive Max , its flagship eye-nutrition formula, features MaquiBright®, the branded, standardized maqui berry extract, at [...]
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
30/09/2026
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
30/09/2026
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE [...]
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
30/09/2026
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- [...]
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
30/09/2026
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced [...]
Ocugen to Participate in Upcoming Scientific Conferences
30/09/2026
MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company [...]
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
30/09/2026
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB [...]
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
30/09/2026
Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in [...]
EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application
30/09/2026
The company is preparing to advance its drug candidate for complex perianal fistulas associated with Crohn’s disease into clinical development and aims to achieve first-in-human administration by the end of the first [...]
More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research
30/09/2026
Three published human studies cover more than 1,600 participants, all testing one complete formulation rather than its separate compounds.*† The earliest study in the set, a prospective trial of 1,236 adults, recorded a [...]

Pages